GlassScriptPhysician profile
Steven Mark Sobol
NPI 1598722712
$239.92
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $49.09 · 2021: $42.03 · 2022: $14.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $29.38 | 2021 | |
| Depuy Synthes Sales INC. | $28.70 | 2019 | |
| Karl Storz Endoscopy-America | $19.43 | 2020 | |
| Olympus America INC. | $17.22 | 2019 | |
| Eisai INC. | $16.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.69 | 2019 | |
| Csl Behring | $16.29 | 2019 | |
| Alk-Abello, INC | $14.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.25 | 2019 | |
| Smith+Nephew, INC. | $14.18 | 2019 | |
| Merck Sharp & Dohme LLC | $14.02 | 2022 | |
| Integra Lifesciences Corporation | $12.97 | 2019 | |
| Tactile Systems Technology INC | $12.96 | 2020 | |
| Ibsa Pharma INC. | $12.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.